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ABSTRACT 
Extracellular vesicles (EVs) including apoptotic bodies (ABs), microvesicles (MVs), exosomes 
(EXOs) and cell derived artificial nanovesicles (NVs) are important mediators of cell-to-cell 
communication, in part by transferring bioactive molecules such as DNA, mRNA, miRNA, siRNA, 
proteins, and lipids. These EVs are released by many cell types, including melanoma cells, and are 
found in many body fluids. EVs derived from various cell types differ in their molecular composition 
making them as important diagnostic and prognostic markers. The overall aim of this thesis was to 
use small-RNA sequencing techniques to define the molecular RNA cargo in the EV subsets 
described above as well as to examine the functional relevance of the EV-associated miRNA and 
siRNA on recipient cells. 
Characterization of EVs showed distinct RNA profiles in ABs, MVs, and EXOs, and there were 
significantly greater amounts of total RNA in EXOs compared to ABs and MVs. Small RNA 
sequencing revealed distinct repertoires of noncoding RNAs in the EV subsets. EXOs contained 
unique sets of miRNAs, which were shown to be differentially expressed in melanoma tumors 
compared with benign naevi in previously published studies, thus making them potentially useful as 
carriers of therapeutic agents. This study demonstrates that distinct sets of RNA molecules are present 
in subsets of EVs, and this provides unique insights into the contribution of extracellular RNA in 
cancer development and progression.  
The BRAFV600E inhibitor vemurafenib inhibited the growth of in vitro melanoma cell cultures, and 
EVs isolated from the treated cells had significantly higher RNA and protein contents compared to 
EVs from non-treated cells. Small RNA sequencing revealed distinct non-coding RNA species with 
significant alterations in miRNA between treated and non-treated cell-derived EVs. Moreover, treated 
cells and the EVs derived from them showed significant upregulation of miR-211 in vitro and in vivo. 
Furthermore, when vemurafenib-treated cell-derived EXOs were transferred to BRAFWT cells, 
KCNMA1 and IGF2R, genes that are known to play roles in tumor progression, were down-regulated 
and this resulted in growth attenuation. Overall, miR-211 could be used as a biomarker of response in 
patients diagnosed with BRAF-mutant melanoma. This study also provides the framework for further 
investigations into the function of miR-211 in melanoma cells and EVs as well as in cells that might 
receive miRNA from EVs. 
Artificial EXO-mimetic NVs were developed by serial extrusion, and they showed similar 
characteristics as EXOs. Exogenous loading of GFP-siRNA in NVs led to down-regulation of GFP in 
endothelial cells. Cell-derived NVs carrying endogenously expressed Myc-siRNA showed significant 
down-regulation of human cMyc both transcriptionally as well as translationally in lymphoma cells. 
These NVs were efficiently loaded with siRNA and were taken up by recipient cells resulting in the 
reduction of target gene expression. In conclusion, this study suggests that EXO-mimetic NVs can be 
a platform for delivering siRNA to cells. 
Taken together, EVs have significant therapeutic potential. EVs have emerged as a novel and 
functionally important vehicle of cell-cell communication that can mediate multiple biological effects. 
In addition, these vesicles might provide unique signatures that can be used as biomarkers of response 
to drug treatment.   
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